EGFR Antibody clinical trials
How each study uses EGFR Antibody is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the EGFR Antibody studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Memorial Sloan Kettering Cancer Center (1) · Sun Yat-sen University (1) · Fudan University (1) · Shanghai Changzheng Hospital (1) · Benaroya Research Institute (1)
Often tested with
Tested in the same studies.
Floxuridine (2) · Gemcitabine (2) · Oxaliplatin (2) · Irinotecan (2) · Fluorouracil (2) · Immune checkpoint inhibitors (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test EGFR Antibody.
- Jun 2027EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaPhase 1/2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses EGFR Antibody is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal CarcinomaRecruitingPhase 1/2Sun Yat-sen UniversityNCT06802835Written as EGFR AntibodyHow we know
- PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyRecruitingPhase 2Fudan UniversityNCT06156878Written as Anti-EGFR and PD-1 inhibitor armHow we know
- A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or CholangiocarcinomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT03693807Written as Anti-EGFR (Panitumumab or Cetuximab)How we know
- EGFR Monoclonal Antibody for Advanced Gastric CancerStatus unknownPhase 2Shanghai Changzheng HospitalNCT04136600Written as EGFR antibody and ChemotherapyHow we know
- A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or CholangiocarcinomaStatus unknownPhase 2Benaroya Research InstituteNCT04668976Written as Anti-EGFR (Panitumumab or Cetuximab)How we know